

PROVIDER Update



CONTRACTUAL | APRIL 11, 2018 | UPDATE 18-223 | 1 PAGE

Medications Newly Approved by the U.S. Food and Drug Administration

Recently, the below medications have been approved by the U.S. Food and Drug Administration (FDA) and require prior authorization immediately. Health Net Community Solutions, Inc. (Health Net), on behalf of CalViva Health, has listed the medications below under Outpatient Pharmaceuticals (Submitted under Medical Benefit) on the prior authorization requirements list.

Medication	FDA Approval Date and Indication
Luxturna™	Approved on December 19, 2017, for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy
Prevymis™	Approved on November 9, 2017, for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
Yescarta™	Approved on October 18, 2017, for relapsed or refractory large-B-cell lymphoma after 2 or more lines of systemic therapy
Zilretta™	Approved on October 6, 2017, for the management of osteoarthritis pain of the knee

ADDITIONAL INFORMATION

Providers are encouraged to access the provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 1-888-893-1569.

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

PROVIDER SERVICES

1-888-893-1569
www.healthnet.com